Atea Pharmaceuticals to highlight strategic priorities for FY26

Atea Pharmaceuticals (AVIR) will present the Company’s strategic priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15 in San Francisco. Atea ended 2025 in a strong financial position with cash and investments in the amount of $301.8 million at December 31, 2025, providing a cash runway that is expected to extend through 2027. Highlights: Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026; Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD Trial Outside North America Expected Year-End 2026; C-BEYOND and C-FORWARD Are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for Treatment of HCV; Initiation of HEV Phase 1 Clinical Program for Product Candidate AT-587 Anticipated Mid-2026